Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16760169 | 1.00 | PDE10A (0.48) | PDE10A | |
| SCHEMBL16769570 | 0.86 | PDE10A (0.48) | PDE10A | |
| SCHEMBL16760235 | 0.86 | PDE10A (0.48) | PDE10A | |
| SCHEMBL16760086 | 0.83 | PDE10A (0.56) | PDE10A | |
| SCHEMBL16760025 | 0.83 | PDE10A (0.56) | PDE10A | |
| SCHEMBL16760037 | 0.83 | PDE10A (0.47) | PDE10A | |
| SCHEMBL16760039 | 0.83 | PDE10A (0.47) | PDE10A | |
| SCHEMBL16760027 | 0.82 | PDE10A (0.50) | PDE10A | |
| SCHEMBL2053430 | 0.82 | PDE10A (0.62) | PDE10A | |
| SCHEMBL2053431 | 0.82 | PDE10A (0.62) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074387-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| EP-3074387-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-9586970-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586970-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586970-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160264585-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264585-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264585-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015078836-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264585-A1 | IMIDAZOLE DERIVATIVES | GRIN2B, MAOB, GRIN2A | PDE10A 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.